Lantern - נכסים נקיים למניה בודדת LTRN

Lantern Pharma Inc. (LTRN) is creating a technological barrier by utilizing AI algorithms to analyze genomic data. The book value per share under RAS confirms effective capital management, where -0.25 captures the current state of the parameter. Asset growth is driven by the sustainable selection of molecules that reduce costs and the strategic outsourcing of laboratory tests to external partners to accelerate drug verification.

Book value per share reflects the intrinsic value of the business, allowing for a comparison between the market capitalization of Lantern Pharma Inc. (LTRN) and the actual volume of net assets. The trend in book value per share demonstrates the effectiveness of capitalizing the AI platform through partnerships, helping investors determine whether the rise in share price is supported by a fundamental increase in equity or merely by expectations of future clinical data.